Literature DB >> 21283128

Hematology: curing CML with imatinib--a dream come true?

Michael Deininger1.   

Abstract

Entities:  

Year:  2011        PMID： 21283128     DOI： 10.1038/nrclinonc.2011.17

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

Authors:  Philippe Rousselot; Francoise Huguet; Delphine Rea; Laurence Legros; Jean Michel Cayuela; Odile Maarek; Odile Blanchet; Gerald Marit; Eliane Gluckman; Josy Reiffers; Martine Gardembas; François-Xavier Mahon
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

2.  Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).

Authors:  Timothy P Hughes; Andreas Hochhaus; Susan Branford; Martin C Müller; Jaspal S Kaeda; Letizia Foroni; Brian J Druker; François Guilhot; Richard A Larson; Stephen G O'Brien; Marc S Rudoltz; Manisha Mone; Elisabeth Wehrle; Vijay Modur; John M Goldman; Jerald P Radich
Journal:  Blood       Date:  2010-08-02       Impact factor: 22.113

3.  Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.

Authors:  John M Goldman; Navneet S Majhail; John P Klein; Zhiwei Wang; Kathleen A Sobocinski; Mukta Arora; Mary M Horowitz; J Douglas Rizzo
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

4.  Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

Authors:  D M Ross; S Branford; J F Seymour; A P Schwarer; C Arthur; P A Bartley; C Slader; C Field; P Dang; R J Filshie; A K Mills; A P Grigg; J V Melo; T P Hughes
Journal:  Leukemia       Date:  2010-09-02       Impact factor: 11.528

5.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

6.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

7.  The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.

Authors:  S Bose; M Deininger; J Gora-Tybor; J M Goldman; J V Melo
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

8.  BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.

Authors:  Mateusz Koptyra; Rafal Falinski; Michal O Nowicki; Tomasz Stoklosa; Ireneusz Majsterek; Margaret Nieborowska-Skorska; Janusz Blasiak; Tomasz Skorski
Journal:  Blood       Date:  2006-03-09       Impact factor: 22.113
  8 in total
  9 in total

1.  Stem cell persistence in chronic myeloid leukemia.

Authors:  M Deininger
Journal:  Leuk Suppl       Date:  2012-08-09

2.  Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Authors:  Naoto Takahashi; Tetsuzo Tauchi; Kunio Kitamura; Koichi Miyamura; Yoshio Saburi; Yoshihiro Hatta; Yasuhiko Miyata; Shinichi Kobayashi; Kensuke Usuki; Itaru Matsumura; Yosuke Minami; Noriko Usui; Tetsuya Fukuda; Satoru Takada; Maho Ishikawa; Katsumichi Fujimaki; Hiroshi Gomyo; Osamu Sasaki; Kohshi Ohishi; Takaaki Miyake; Kiyotoshi Imai; Hitoshi Suzushima; Hideki Mitsui; Kazuto Togitani; Toru Kiguchi; Yoshiko Atsuta; Shigeki Ohtake; Kazunori Ohnishi; Yukio Kobayashi; Hitoshi Kiyoi; Yasushi Miyazaki; Tomoki Naoe
Journal:  Int J Hematol       Date:  2017-09-19       Impact factor: 2.490

Review 3.  Development of an effective therapy for chronic myelogenous leukemia.

Authors:  David W Woessner; Carol S Lim; Michael W Deininger
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

Review 4.  Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.

Authors:  Ai Inoue; Chiharu I Kobayashi; Haruka Shinohara; Kenichi Miyamoto; Nobuhiko Yamauchi; Junichiro Yuda; Yukihiro Akao; Yosuke Minami
Journal:  Int J Hematol       Date:  2018-08-28       Impact factor: 2.490

Review 5.  Issues in current management of chronic myeloid leukemia: Importance of molecular monitoring on long term outcome.

Authors:  Hari Menon
Journal:  South Asian J Cancer       Date:  2013-01

6.  CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells.

Authors:  Guoqiang Chang; Hongju Zhang; Jian Wang; Yujuan Zhang; Hua Xu; Chijuan Wang; Hairui Zhang; Li Ma; Qinghua Li; Tianxiang Pang
Journal:  Cancer Cell Int       Date:  2013-11-20       Impact factor: 5.722

7.  Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.

Authors:  Jean Claude Chomel; Marie-Laure Bonnet; Nathalie Sorel; Ivan Sloma; Annelise Bennaceur-Griscelli; Delphine Rea; Laurence Legros; Anne Marfaing-Koka; Jean-Henri Bourhis; Shanti Ame; Agnès Guerci-Bresler; Philippe Rousselot; Ali G Turhan
Journal:  Oncotarget       Date:  2016-06-07

8.  Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.

Authors:  Naoto Takahashi; Kaichi Nishiwaki; Chiaki Nakaseko; Nobuyuki Aotsuka; Koji Sano; Chikako Ohwada; Jun Kuroki; Hideo Kimura; Michihide Tokuhira; Kinuko Mitani; Kazuhisa Fujikawa; Osamu Iwase; Kohshi Ohishi; Fumihiko Kimura; Tetsuya Fukuda; Sakae Tanosaki; Saori Takahashi; Yoshihiro Kameoka; Hiroyoshi Nishikawa; Hisashi Wakita
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

Review 9.  The concept of treatment-free remission in chronic myeloid leukemia.

Authors:  S Saußele; J Richter; A Hochhaus; F-X Mahon
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.